NCT04984707View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetics of KX826 in Healthy Male Subjects With Androgenetic Alopecia Following Topical Single Ascending Dose Administration

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 28, 2019

Primary Completion Date

April 11, 2019

Study Completion Date

October 24, 2019

Conditions
Androgenetic Alopecia
Interventions
DRUG

KX0826

AR antagonist

OTHER

Placebo

Placebo of KX-826

Trial Locations (1)

33136

inVentiv Health Clinical Research Services LLC, Miami

All Listed Sponsors
lead

Suzhou Kintor Pharmaceutical Inc,

INDUSTRY

NCT04984707 - Safety, Tolerability and Pharmacokinetics of KX826 in Healthy Male Subjects With Androgenetic Alopecia Following Topical Single Ascending Dose Administration | Biotech Hunter | Biotech Hunter